ERBB2 and breast cancer: As observed in Figure 4A, LN− patients bearing HER2-amplified tumors exhibited the greater levels of lipid peroxides when compared to those with luminal B (p = 0.0108) and triple-negative (p = 0.060) breast cancer (1583200 ± 303356 RLU for Luminal A, 1159332 ± 233005 RLU for Luminal B, 1249340 ± 507052 RLU for Luminal-HER2, 2782307 ± 697733 RLU for HER2, 1068190 ± 193395 RLU for triple-negative).